Martine Piccart's guest appearances

Martine Piccart

Les derniers podcasts de la RTBF.be

Investigating Breast Cancer

2012 Oncopolicy Forum

4th IMPAKT Breast Cancer Conference

Larry Norton

Walter Willett

Michael Clarke

Mark Robson

Lewis Cantley

Mina Bissell

Lawrence Shulman

Jack Cuzick

Fabrice Andre

Luca Gianni

Alan Ashworth

Lori Pierce

Jan Geissler

Richard Finn

Hedvig Hricak

OwlTail

Dr. Martine Piccart talks to us about the power of collaboration in metastatic breast cancer research Metastasis, the spread of cancer cells from the breast to other sites in the body, is responsible for nearly all breast cancer deaths. Approximately 150,000 men and women are diagnosed with metastatic breast cancer each year. Today, BCRF is the largest private funder of this critical area of research. Dr. Martine Piccart is passionate about metastasis research and the vital role that international collaboration plays in her work. A BCRF investigator since 2004, Dr. Piccart’s research aims to better understand the origins of metastatic breast cancer and how it evolves. Through the Breast International Group (BIG), she oversees the AURORA-EU study, the Belgium-based arm of the Evelyn H. Lauder Founder’s Fund for Metastatic Breast Cancer Research. Named for BCRF’s founder, the Founder’s Fund is a multi-year, international collaboration. In 2019, AURORA-EU presented findings on the molecular differences between metastatic cells and other tumor cells, revealing a new avenue of research including the potential for targeted treatments. Dr. Piccart is Professor of Oncology at the Université Libre de Bruxelles, Belgium, and Director of Medicine at the Institut Jules Bordet. She is also the co-founder and chair of BIG, which unites 55 academic research groups from around the world, running over 30 trials, and developing numerous research programs.

Dr. Martine Piccart talks to us about the power of collaboration in metastatic breast cancer research Metastasis, the spread of cancer cells from the breast to other sites in the body, is responsible for nearly all breast cancer deaths. Approximately 150,000 men and women are diagnosed with metastatic breast cancer each year. Today, BCRF is the largest private funder of this critical area of research. Dr. <a href="https://www.bcrf.org/martine-j-piccart-gebhart" rel="nofollow" target="_blank">Martine Piccart</a> is passionate about metastasis research and the vital role that international collaboration plays in her work. A BCRF investigator since 2004, Dr. Piccart’s research aims to better understand the origins of metastatic breast cancer and how it evolves. Through the Breast International Group (BIG), she oversees the AURORA-EU study, the Belgium-based arm of the <a href="https://www.bcrf.org/evelyn-h-lauder-founders-fund-metastatic-breast-cancer-research" rel="nofollow" target="_blank">Evelyn H. Lauder Founder’s Fund for Metastatic Breast Cancer Research</a>. Named for BCRF’s founder, the Founder’s Fund is a multi-year, international collaboration. In 2019, AURORA-EU presented findings on the molecular differences between metastatic cells and other tumor cells, revealing a new avenue of research including the potential for targeted treatments. Dr. Piccart is Professor of Oncology at the Université Libre de Bruxelles, Belgium, and Director of Medicine at the Institut Jules Bordet. She is also the co-founder and chair of BIG, which unites 55 academic research groups from around the world, running over 30 trials, and developing numerous research programs.

Unraveling Metastatic Breast Cancer, with Dr. Martine Piccart 

Prof Martine Piccart warns that although there has been rapid progress in development of personalised cancer treatment, there is still a shortage of diagnostic tests and effective prognostic biomarkers to identify which patients will respond to treatments or eventually relapse. Without this oncologists will continue to over-treat many patients and waste valuable funds. Prof Piccart concludes by commenting that personalised medicine is currently simply stratified medicine and explains what progress must be made personalised medicine is achieved in full.

Prof Martine Piccart warns that although there has been rapid progress in development of personalised cancer treatment, there is still a shortage of diagnostic tests and effective prognostic biomarkers to identify which patients will respond to treatments or eventually relapse. Without this oncologists will continue to over-treat many patients and waste valuable funds. Prof Piccart concludes by commenting that personalised medicine is currently simply stratified medicine and explains what progress must be made personalised medicine is achieved in full.

Progress of personalised oncology treatment: Prof. Martine Piccart – President-Elect of ECCO

Prof Martine Piccart talks to ecancer about heterogeneity of breast cancer tumours, advancements in technology and the future of treating breast cancer at IMPAKT 2012 in Brussels, May 2012. IMPAKT 2012 focused on the latest developments in translational research, teaching young oncologists on how to treat patients in the coming years and especially on the heterogeneity of tumours. New technologies hold the potential for understanding the evolution of breast cancer and the differences between primary tumours and metastases. With HER+ tumours, each type of tumour, slow growing and highly proliferating, hold very specific molecular characteristics that can potentially unlock new understandings of the disease through the patient's immune system and the microenvironment.

Prof Martine Piccart talks to ecancer about heterogeneity of breast cancer tumours, advancements in technology and the future of treating breast cancer at IMPAKT 2012 in Brussels, May 2012. IMPAKT 2012 focused on the latest developments in translational research, teaching young oncologists on how to treat patients in the coming years and especially on the heterogeneity of tumours. New technologies hold the potential for understanding the evolution of breast cancer and the differences between primary tumours and metastases. With HER+ tumours, each type of tumour, slow growing and highly proliferating, hold very specific molecular characteristics that can potentially unlock new understandings of the disease through the patient's immune system and the microenvironment.

Highlights and goals of IMPAKT 2012: Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium